Navigation Links
Queensland technology licensed by billion-dollar US company
Date:2/15/2008

University of Queensland scientists have developed a proprietary technology that will help other researchers in understanding fundamental aspects of growth, development, and disease, which has been licensed to one of the world's largest life science technology companies.

Dr Marcel Dinger and Professor John Mattick, from UQ's Institute for Molecular Bioscience, have designed a new type of microarray RNA chip, used by researchers to analyse which genes are being expressed at any one time in a particular cell.

The technology has been licensed through IMBcom, UQ's company for the commercialisation of intellectual property arising from research conducted at the IMB. It was licensed to Invitrogen, a provider of essential life science technologies for research, production and diagnostics with a 2006 revenue of US$1.15 billion.

Every cell in the body contains a full set of genes, but different cells express different subsets, Professor Mattick said. In the past these genes were thought only to code mainly for proteins, via the production of "messenger RNAs", but it is now evident that many other genes produce non-coding RNAs whose functions have yet to be determined.

It appears that we have misunderstood the nature of genetic programming in humans and other complex organisms, Professor Mattick said. Most of the genome is transcribed, mainly into non-coding RNAs, which appear to comprise a hidden layer of gene regulation whose full dimensions are just beginning to be explored.

There is increasing recognition that these non-coding RNAs control various levels of gene expression in physiology and development, as well as in the brain.

Products commercialized by Invitrogen will be based on a novel set of RNA probes that Dr Dinger and Professor Mattick have designed, which can uniquely identify tens of thousands of coding and non-coding RNA sequences. This is the first time that one product has been able to identify both large numbers of protein-coding and non-coding RNAs.

This technology will allow researchers to obtain more accurate information about the relationship between messenger and non-coding RNA expression, Dr Peter Isdale, CEO of IMBcom, said. It has the potential to make a real impact in cancer and stem cell research, as these RNAs are implicated in both of these areas.


'/>"/>

Contact: Bronwyn Adams
communications@uq.edu.au
61-733-462-134
Research Australia
Source:Eurekalert

Related medicine news :

1. Fluoridated water for Queensland ... at last
2. Queensland businessman is one in a million
3. QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravos The Real Housewives of Orange County
4. Quantum light beams good for fast technology
5. New Smart Technology Makes Patient Data Collection Easier, More Efficient
6. Align Technology Executive to Present at Upcoming Financial Conferences
7. Pioneer Surgical Technology Hires Vice President of New Business Development
8. Purdue researchers develop technology to detect cancer by scanning surface veins
9. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
10. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
11. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... modern procedure that achieves results in a fraction of the time as traditional ... NV, with Significance Dental Specialists, now offers this revolutionary treatment with or without ...
(Date:4/25/2017)... ... ... Back Pain Centers of America (BPC), which connects people searching ... area, announces the launch of a new and proprietary customer relationship management (CRM) system ... physicians to help them with back or neck pain and helps to match them ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, ... to its patient care management module. Using this new feature, sleep physicians can ... been initiated on continuous positive airway pressure (CPAP), oral, or other forms of ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology: